Edinburgh, United Kingdom; 20th August 2024
Fitabeo Therapeutics, a clinical-stage specialty pharmaceutical company and University of Strathclyde spin-out has announced the grant of a new patent for its groundbreaking drug delivery technology in Japan. This significant milestone marks a key advancement in Fitabeo Therapeutics’ mission to develop treatments and improve health outcomes through pioneering pharmaceutical solutions.
SpherionexT is a cutting-edge controlled-release film technology designed to enhance the efficacy, safety, and patient compliance of various therapeutic agents by improving the precision and control of drug release within the body. This technology is expected to revolutionise the treatment landscape for a variety of chronic and acute medical conditions. This intellectual property grant indicates the company’s dedication to addressing critical healthcare challenges and improving patient care with innovative approaches.
Prof. Alex Mullen, Chief Scientific Officer of Fitabeo Therapeutics, said, “We are incredibly proud to have received this patent, which underscores our commitment to innovation and excellence in drug delivery systems. This recognition validates our innovative technology and reinforces our commitment to advancing pharmaceutical research. SpherionexT has the potential to significantly improve patient outcomes and set new standards in the treatment of various diseases. This patent is a testament to the hard work and dedication of our research and development team and reflects our collaboration with the University of Strathclyde to deliver impactful medicines.”
The granting of this patent strengthens Fitabeo Therapeutics’ intellectual property portfolio and solidifies its position in the pharmaceutical industry. Besides developing its pipeline of innovative medicines, the company is actively exploring partnerships and licensing opportunities to bring this transformative technology to market and benefit patients worldwide.
Director Of Innovation & Industry Engagement at the University of Strathclyde, Meryl Levington, said, “We are delighted that the Japanese patent for the oral thin film technology developed at the University has been granted.
“We are hopeful that the other patent territories will follow suit, increasing investor attractiveness to ultimately speed up the process of bringing new medicines to market.”
Notes to Editors:
For further information, please contact:
Mohini Kochrekar, Communications Manager, Fitabeo Therapeutics
Email: [email protected]
Lynn McPherson, Communications Officer, University of Strathclyde
Email: [email protected]
About Fitabeo Therapeutics:
Fitabeo Therapeutics is a clinical-stage speciality pharmaceutical company that develops and commercialises a differentiated portfolio of innovative medicines focusing on indications where existing treatments are inadequate for the target population. It deploys breakthrough technologies to develop medicines that enable patient autonomy, decentralise patient care, and provide superior health outcomes.
About University of Strathclyde:
The University of Strathclyde is a leading international technological university based in the centre of Glasgow.
Inspired by our founding principle as ‘a place of useful learning’, our mission is to make a positive difference to the lives of our students, to society and to the world.
Strathclyde students benefit from an innovative and practical educational experience enhanced by its integration with our research capabilities, high-quality academic resources and an unparalleled industry engagement programme.
The excellence of our research is evidenced by the growth in range and scale of our research collaborations and by our performance in the Research Excellence Framework 2021, where almost 90% was rated ‘world-leading’ or ‘internationally-excellent’.
We have redefined how we collaborate and work with industry, government and the third sector to ensure innovation and knowledge exchange are fundamental activities that deliver tangible impact.
Strathclyde was named Scottish University of the Year 2024 in the inaugural Daily Mail University Guide, Sunday Times Good University Guide Scottish University of the Year 2020, Times Higher Education UK University of the Year 2019, and was awarded a Queen’s Anniversary Prize for Higher and Further Education for its excellence in energy innovation in 2020, for excellence in advanced manufacturing in 2022 and for excellence in photonics research in 2023.
-ends-
This press release contains forward-looking statements that are subject to risks and uncertainties. Actual results may differ materially from those expressed or implied in these statements.
